Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania

被引:10
作者
Mwaiswelo, Richard [1 ,2 ]
Ngasala, Billy [1 ,3 ]
Jovel, Irina [4 ]
Xu, Weiping [4 ]
Larsson, Erik [4 ]
Malmberg, Maja [5 ,6 ]
Gil, Jose Pedro [3 ,7 ]
Premji, Zul [8 ]
Mmbando, Bruno P. [9 ]
Martensson, Andreas [3 ]
机构
[1] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol & Med Entomol, POB 65011, Dar Es Salaam, Tanzania
[2] Hubert Kairuki Mem Univ, Dept Microbiol & Parasitol, Dar Es Salaam, Tanzania
[3] Uppsala Univ, Dept Womens & Childrens Hlth, Int Maternal & Child Hlth IMCH, Uppsala, Sweden
[4] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[5] Swedish Univ Agr Sci, Virol Sect, Dept Biomed Sci & Vet Publ Hlth, Uppsala, Sweden
[6] Swedish Univ Agr Sci, Dept Anim Breeding & Genet, SLU Global Bioinformat Ctr, Uppsala, Sweden
[7] Karolinska Inst, Div Pharmacogenet, Dept Physiol & Pharmacol, Drug Resistance Unit, Stockholm, Sweden
[8] Aga Khan Univ Hosp, Nairobi, Kenya
[9] Natl Inst Med Res, Tanga Ctr, Dept Stat & Epidemiol, Tanga, Tanzania
基金
瑞典研究理事会;
关键词
ARTEMISININ RESISTANCE; COMBINATION THERAPY; CHILDREN; CHLOROQUINE; CLEARANCE; PARASITES; AMODIAQUINE; ARTESUNATE; ALLELES; GENE;
D O I
10.4269/ajtmh.18-0729
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Prevalence of and risk factors associated with polymerase chain reaction (PCR)-determined Plasmodium falciparum positivity were assessed on day 3 after initiation of treatment, pre-implementation and up to 8 years post-deployment of artemether-lumefantrine as first-line treatment for uncomplicated malaria in Bagamoyo district, Tanzania. Samples originated from previously reported trials conducted between 2006 and 2014. Cytochrome b-nested PCR was used to detect malaria parasites from blood samples collected on a filter paper on day 3. Chi-square and McNemar chi-squared tests, logistic regression models, and analysis of variance were used as appropriate. Primary outcome was based on the proportion of patients with day 3 PCR-determined P. falciparum positivity. Overall, 256/584 (43.8%) of screened patients had day 3 PCR-determined positivity, whereas only 2/584 (0.3%) had microscopy-determined asexual parasitemia. Day 3 PCR-determined positivity increased from 28.0% (14/50) in 2006 to 74.2% (132/178) in 2007-2008 and declined, thereafter, to 36.0% (50/139) in 2012-2013 and 27.6% (60/217) in 2014. When data were pooled, pretreatment microscopy-determined asexual parasitemia >= 100,000/mu L, hemoglobin < 10 g/dL, age < 5 years, temperature >= 37.5 degrees C, and year of study 2007-2008 and 2012-2013 were significantly associated with PCR-determined positivity on day 3. Significant increases in P. falciparum multidrug resistance gene 1 N86 and P. falciparum chloroquine resistant transporter K76 across years were not associated with PCR-determined positivity on day 3. No statistically significant association was observed between day 3 PCR-determined positivity and PCR-adjusted recrudescence. Day 3 PCR-determined P. falciparum positivity remained common in patients treated before and after implementation of artemether-lumefantrine in Bagamoyo district, Tanzania. However, its presence was associated with pretreatment characteristics.
引用
收藏
页码:1179 / 1186
页数:8
相关论文
共 12 条
  • [1] Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania
    Mhamilawa, Lwidiko E.
    Wikstrom, Sven
    Mmbando, Bruno P.
    Ngasala, Billy
    Martensson, Andreas
    MALARIA JOURNAL, 2020, 19 (01)
  • [2] Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania
    Lwidiko E. Mhamilawa
    Sven Wikström
    Bruno P. Mmbando
    Billy Ngasala
    Andreas Mårtensson
    Malaria Journal, 19
  • [3] Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania
    Mwaiswelo, Richard
    Ngasala, Billy
    Gil, J. Pedro
    Malmberg, Maja
    Jovel, Irina
    Xu, Weiping
    Premji, Zul
    Mmbando, Bruno P.
    Bjorkman, Anders
    Martensson, Andreas
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (02) : 526 - 532
  • [4] Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial
    Mhamilawa, Lwidiko E.
    Ngasala, Billy
    Morris, Ulrika
    Kitabi, Eliford Ngaimisi
    Barnes, Rory
    Soe, Aung Paing
    Mmbando, Bruno P.
    Bjoerkman, Anders
    Martensson, Andreas
    MALARIA JOURNAL, 2020, 19 (01)
  • [5] Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda
    Angwe, Martin Kamilo
    Mwebaza, Norah
    Nsobya, Sam Lubwama
    Vudriko, Patrick
    Dralabu, Saviour
    Omali, Denis
    Tumwebaze, Maria Agnes
    Ocan, Moses
    PLOS ONE, 2024, 19 (06):
  • [6] High prevalence of persistent residual parasitemia on days 3 and 14 after artemether-lumefantrine or pyronaridine-artesunate treatment of uncomplicated Plasmodium falciparum malaria in Nigeria
    Funwei, Roland I.
    Uyaiabasi, Gabriel N.
    Hammed, Wasiu A.
    Ojurongbe, Olusola
    Walker, Oladapo
    Falade, Catherine O.
    PARASITOLOGY RESEARCH, 2023, 122 (02) : 519 - 526
  • [7] Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
    Abate, Bontu
    Brhane, Bokretsion Gidey
    Manyazewal, Tsegahun
    Mohammed, Hussien
    Wuletaw, Yonas
    Kassa, Moges
    Hailu, Mesay
    Tollera, Getachew
    Tasew, Geremew
    Assefa, Ashenafi
    Makonnen, Eyasu
    MALARIA JOURNAL, 2025, 24 (01)
  • [8] Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial
    Obonyo, Charles O.
    Juma, Elizabeth A.
    Were, Vincent O.
    Ogutu, Bernhards R.
    MALARIA JOURNAL, 2022, 21 (01)
  • [9] Efficacy and Effectiveness of Artemether-Lumefantrine after Initial and Repeated Treatment in Children &lt; 5 Years of Age with Acute Uncomplicated Plasmodium falciparum Malaria in Rural Tanzania: A Randomized Trial
    Ngasala, Billy E.
    Malmberg, Maja
    Carlsson, Anja M.
    Ferreira, Pedro E.
    Petzold, Max G.
    Blessborn, Daniel
    Bergqvist, Yngve
    Gil, Jose P.
    Premji, Zul
    Bjoerkman, Anders
    Martensson, Andreas
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (07) : 873 - 882
  • [10] K13 Propeller Alleles, mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015
    Montenegro, Madeline
    Neal, Aaron T.
    Posada, Maritza
    De las Salas, Briegel
    Lopera-Mesa, Tatiana M.
    Fairhurst, Rick M.
    Tobon-Castano, Alberto
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (12)